|
May 14
|
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
|
|
May 14
|
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
|
|
Apr 24
|
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
|
|
Apr 24
|
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
|
|
Apr 17
|
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
|
|
Apr 4
|
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
|
|
Apr 1
|
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
|
|
Mar 28
|
Affimed Reports 2023 Financial Results and Operational Progress
|
|
Mar 21
|
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
|
|
Mar 14
|
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
|
|
Mar 6
|
Affimed Announces 1-for-10 Reverse Stock Split
|
|
Jan 8
|
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
|
|
Dec 11
|
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
|
|
Dec 11
|
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
|
|
Dec 4
|
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
|
|
Nov 14
|
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
|
|
Nov 9
|
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
|
|
Nov 7
|
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
|
|
Nov 3
|
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
|
|
Nov 2
|
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
|